Carbohydrate metabolic disturbances in gout: Detection rate and clinical features

Terapevticheskii Arkhiv

Volumn 82, Issue 5, 2010, Pages 50-54

  Eliseev, M S ^a   Barskova, V G ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

Carbohydrate metabolic disturbances; Gout; Type 2 diabetes

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ANTHROPOMETRY; ARTICLE; BLOOD; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; GOUT; HUMAN; INCIDENCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANTHROPOMETRY; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; GOUT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TRIGLYCERIDES; URIC ACID;

EID: 77954252173     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Vazguez-Mellado J., Garsia C. G., Vazguez S. G. et al. Metabolic syndrome and ischemic heart disease in gout. J. Clin. Rheumatol. 2004; 10 (3): 105-109.
2. Rho Y. H., Choi S. J., Lee Y. H. et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study. J. Korean Med. Sci. 2005; 20: 1029-1033.
3. Grundy S. M., Cleeman J. I., Daniels S. R. et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112 (17): 2735-2752.
4. Wilson P. W., D'Agostino R. B., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112 (20): 3066-3072.
5. Ford E. S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabet. Care 2005; 28 (7): 1769-1778.
6. Krishnan E., Baker J. F., Daniel E. F., Schumacher H. R. Gout and the risk of acute myocardial infarction. Arthr. and Rneum. 2006; 54 (8): 2688-2696.
7. Kim S. Y., De Vera M. A., Choi H. K. Gout and mortality. Clin. Exp. Rheumatol. 2008; 26 (5, suppl. 51): S115-S119.
8. Dehghan A., Van Hoek M., Sijbrands E. J. et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabet. Care 2008; 31: 361-362.
9. Arromdee E., Michel C. J., Crowson C. S. et al. Epidemiology of gout: Is the incidence rising? J. Rheumatol. 2002; 29: 2403-2406.
10. Nan H., Qiao Q., Soderberg S. et al. Serum uric acid and incident diabetes in Mauritian Indian and Creole populations. Diabet. Res. Clin. Pract. 2008; 80 (2): 321-327.
11. Vuorinen-Markkola H., Yki-Jarvinen H. Hyperuricemia and insulin resistance. J. Clin. Endocrinol. 1994; 78 (1): 25-29.
12. Bedir A., Topbas M., Tanyeri F. et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn. Heart J. 2003; 44 (4): 527-536.
13. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabet. Metab. 2003; 29 (4, pt 2): 6S9-6S18.
14. Huang E. S., Basu A., O'Grady M., Capretta J. C. Projecting the future diabetes population size and related costs for the U. S. Diabet. Care 2009; 32 (12): 2225-2229.
15. Wallace S. L., Robinson H., Mast A. T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr. and Rheum. 1977; 20: 895-900.
16. Zhang W., Doherty M., Pascuat-Gomez E. et al. EULAR evidence based recommendation for the diagnosis and management of gout. Ann. Rheum. Dis. 2005; 64 (suppl. III): 501.
17. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006.
18. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502.
19. Annemans L., Spaepen E., Gaskin M. et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann. Rheum. Dis. 2008; 67: 960-966.
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet. Care 1997; 20: 1183-1197.
21. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-654.
22. Shaw J. E., de Courten M., Boyko E. J. et al. Impact of new diagnostic criteria for diabetes on different populations. Diabet. Care 1999; 22: 762-766.
23. Saaristo T. E., Barengo N. C., Korpi-Hyovalti E. et al. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. BMC Publ. Hlth 2008; 8: 423.
24. Hofso D., Jenssen T., Hager H. et al. Fasting "Plasma Glucose in the screening for type 2 diabetes in morbidly obese subjects. Obes. Surg. 2009 Dec 1. [Epub ahead of print].
25. Niskanen L., Laaksonen D. E., Lindstrom J. et al. Serum uric acid as a Harbinger of metabolic outcome in subjects with impaired glucose tolerance: The Finnish Diabetes Prevention Study. Diabet. Care 2006; 29 (3): 709-711.
26. Choi H. K., De Vera M. A., Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008; 47 (10): 1567-1570.
27. Poje M., Rocic B. Diabetogenic action of alloxan-like derivatives of uric acid. Experientia 1980; 36: 78-79.
28. Dominis M., Rocic S., Ashcroft S. J. H. et al. Diabetogenic action of alloxan-like compounds: cytoxic effects of 5-hydroxypseudouric acid and dehydrouramil hydratehydrochloride on rat pancreatic β-cells. Diabetologia 1984; 27: 403-406.
29. Butler R., Morris A. D., Belch J. J. et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751.
30. Maedler K., Sergeev P., Ris F. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002; 110: 851-860.
31. Nakagawa T., Hu H., Zharikov S. et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 2006; 290: F625-F631. (Pubitemid 43724964)
32. Augustin R., Carayannopoulos M. O., Dowd L. O. et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J. Biol. Chem. 2004; 279: 16229-16236.
33. Brandstatter A., Kiechl S., Kollertis B. et al. Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. Diabet. Care 2008; 31: 1662-1667.
34. Cheng X., Zhang H. Serum retinal-binding protein 4 is positively related to insulin resistance in Chinese subjects with type 2 diabetes. Diabet. Res. Clin. Pract. 2009; 84 (1): 58-60.
35. Chang Y. H., Lin K. D., Wang C. L. et al. Elevated serum retinol-binding protein 4 concentrations are associated with renal dysfunction and uric acid in type 2 diabetic patients. Diabet. Metab. Res. Rev. 2008; 24 (8): 629-634.
36. Chen C. C., Wu J. Y., Chang C. T. et al. Levels of retinol-binding protein 4 and uric acid in patients with type 2 diabetes mellitus. Metabolism 2009; 58 (12): 1812-1816.
37. Lee S. J., Hirsch J. D., Terkeltaub R. et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology 2009; 48: 582-586.